Relapsing-Remitting Multiple Sclerosis (MS) Market Trends, Demand, Share, Major Player, Competitive Outlook Forecast to 2020-2027
Relapsing-Remitting Multiple Sclerosis (MS) Market Research Report: By Treatment (Immunomodulating Drugs, Nrf2 Activators, Interferons, Others), By Route of Administration (Oral, Intravenous) and By End-User (Hospitals, Clinics, Others) – Forecast to 2027 Market Highlights According to MRFR analysis, the global relapsing-remitting (MS) market is expected to register a CAGR of 3.1% during the forecast period of 2019 to 2025 and held a value of USD 4,976 million in 2018. Relapsing-remitting MS is characterized by attacks of new or increasing neurologic symptoms. These attacks are also called relapses or exacerbations and are followed by periods of partial or complete recovery. Approximately 85% of people with MS are initially diagnosed with relapsing-remitting MS. The growth of the global relapsing-remitting MS market is boosted by various factors such as rising research in the multiple sclerosis treatment fields, and increasing innovations by significant players. However, the stringen